Dr. Kantarjian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Box 428
Houston, TX 77030Phone+1 713-792-6161- Is this information wrong?
Education & Training
- University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1981 - 1983
- American University of Beirut Faculty of MedicineClass of 1979
- American University of BeirutB.S., Science, 1975
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 1983 - 2025
- GA State Medical License 2023 - 2025
- TN State Medical License 2023 - 2024
- AZ State Medical License 2023 - 2024
- OK State Medical License 2020 - 2024
- MS State Medical License 2023 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Fellow of the American Society of Clinical Oncology American Society of Clinical Oncology, 2018
- Lifetime Achievement Award American Lebanese Medical Association, 2015
- National Physician of the Year Award for Lifetime Achievement Castle Connolly Medical Ltd, 2014
- Join now to see all
Clinical Trials
- Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Start of enrollment: 1998 Mar 01
- Clofarabine in Chronic Lymphocytic Leukemia Start of enrollment: 1999 Feb 01
- Study of Three Different Schedules of Low-Dose Decitabine in Myelodysplastic Syndrome (MDS) Start of enrollment: 2003 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Exploring the landscape of somatic ASXL2 mutations in myeloid neoplasms: Frequency and clinical implications.Tareq Abuasab, Gautam Borthakur, Rashmi Kanagal-Shamanna, Lucia Masarova, Keyur Patel, Koichi Takahashi, Prithviraj Bose, John Villarreal, Sherry Pierce, Tapan Kadia, ...> ;American Journal of Hematology. 2024 Apr 13
- Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing ...Lewis F Nasr, Jayastu Senapati, Rebecca Garris, Farhad Ravandi, Nicholas J Short, Elias Jabbour, Nitin Jain, Fadi G Haddad, Ghayas C Issa, Koji Sasaki, Partow Kebriaei...> ;American Journal of Hematology. 2024 Apr 12
- Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.Elias Jabbour, Fadi G Haddad, Koji Sasaki, Bing Z Carter, Yesid Alvarado, Cedric Nasnas, Lewis Nasr, Lucia Masarova, Naval Daver, Naveen Pemmaraju, Nicholas J Short, J...> ;Cancer. 2024 Apr 9
- Join now to see all
Journal Articles
- Characteristics of Patients with Myeloproliferative Neoplasms with Lymphoma, with or Without JAK Inhibitor TherapyNaveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Srdan Verstovsek, Blood
- Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid LeukemiaBrian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
- CD123 Expression Patterns and Selective Targeting with a CD123-Specific Antibody-Drug Conjugate (IMGN632) in Acute Lymphoblastic LeukemiaL Jeffrey Medeiros, Hagop M Kantarjian, Jeffrey L Jorgensen, Marina Konopleva, Elias J Jabbour, Joseph D Khoury, Sa A Wang, Sergej N Konoplev, Haematologica
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Outcome of Patients (Pts) with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) without 3-Month Complete Molecular Response (CMR)Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Ultra-Accurate Assessment of Pretreatment ABL1 Kinase Domain (KD) Mutations in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic...Hagop M. Kantarjian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Medical Crossfire¬: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia _ How the Experts Think and Treat61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a l...2019 ASCO Annual Meeting - 6/1/2019
- Join now to see all
Other
- Patients Take Action Against Cancer Drug PricesKantarjian H, The Houston Chronicle
1/1/2015 - High Cost of Cancer Drugs Goes Beyond the PriceKantarjian H, Modern Healthcare
http://www.modernhealthcare.com/article/20150404/MAGAZINE/304049978
1/1/2015 - Expanding Medicaid under ACA Would Avert State Health CrisisKantarjian H, Ho V, The Houston Chronicle
1/1/2015 - Join now to see all
Authored Content
- L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-Induced HyperbilirubinemiaFebruary 2018
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017
- Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid MalignanciesOctober 2017
- The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II TrialOctober 2017
- Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 Days (SGI5), 10 Days (SGI10), 5 Days + Idarubicin (SGI5 + Ida), and 5 Days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian DesignOctober 2017
- A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (Pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)October 2017
- Join now to see all
Press Mentions
- MD Anderson Research Highlights: ASCO 2023 Special EditionMay 25th, 2023
- Hagop Kantarjian, MD, Honored by ASCO for Leukemia ResearchMay 15th, 2023
- MD Anderson Research Highlights for May 10, 2023May 10th, 2023
- Join now to see all
Grant Support
- University Of Texas M.D. Anderson Cancer Center Spore - LeukemiaNational Cancer Institute2011
- Career Development ProgramNational Cancer Institute2008–2011
- New Approaches To The Biology And Treatment Of Myelodysplastic Syndromes (MDS)National Cancer Institute2008–2009
- University Of Texas M.D. Anderson Cancer Spore-LeukemiaNational Cancer Institute2003–2004
- Combined Modality Therapy To Suppress Philadelphia Chromosome Cells In CMLNational Cancer Institute1998–2002
- Chemotherapy Programs To Generate Diploid Cells For Autologous BMTNational Cancer Institute1996–1997
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas
External Links
- MD Anderson Leukemia Centerhttp://mdanderson.org/leukemiacenter
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: